FDA Approves Gilead's Bixlenvo, First Single-Tablet Regimen for Complex HIV

The U.S. FDA approved Gilead Sciences’ Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg) on August 27, 2026, clearing the first and only once-daily single-tablet regimen (STR) for virologically suppressed adults with HIV who are on complex regimens and cannot take currently available STRs. It is also the smallest STR on the market, and the approval landed on the drug’s August 27 PDUFA date.

Gilead shares closed at $148.86 on approval day, up 0.52%, a sign the market had already priced in the decision.

Bixlenvo pairs bictegravir, the guideline-recommended integrase strand transfer inhibitor with a high resistance barrier that anchors Gilead’s blockbuster Biktarvy, with lenacapavir, a first-in-class capsid inhibitor with a novel mechanism and no cross-resistance to other antiretrovirals. Together the two components target multiple stages of the HIV life cycle.

The approval rests on the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, which showed Bixlenvo maintained virologic suppression at Week 48 on par with both complex multi-tablet regimens and Biktarvy itself. ARTISTRY-1 enrolled the oldest population of any registrational Phase 3 HIV treatment trial to date: median age 60, median 28 years on therapy, and about 40% taking antiretroviral therapy more than once daily. Two-thirds of participants (67%) had NRTI resistance, and 81% were on a complex regimen because of resistance. The most common adverse reactions were headache (4%), nausea (3%), and diarrhea (2%).

Bixlenvo requires a two-day initiation with Sunlenca (lenacapavir), after which patients take a single Bixlenvo tablet once daily. Gilead set the list price at $4,595 for a 30-day supply, in line with other daily single-tablet HIV regimens, according to CNBC.

The clinical win is real, but the incremental market is narrow. Gilead estimates complex-regimen patients make up roughly 5% or more of adults living with HIV in the U.S., and much of Bixlenvo’s early uptake will come from patients switching off Gilead’s own Biktarvy, which generated $14.33 billion in 2025. We laid out that cannibalization tension ahead of the decision in our analysis of the BIC/LEN franchise. The muted stock move confirms investors see the approval as priced in.

Gilead is framing Bixlenvo as the first of a pipeline of daily, weekly, and longer-acting options built around lenacapavir. The more consequential catalyst remains the once-weekly islatravir/lenacapavir pill (ISL/LEN) being developed with Merck, which reported positive Phase 3 topline results in June and carries a February 2027 PDUFA.